{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:04Z","timestamp":1793051104121,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2020JJ5938"],"award-info":[{"award-number":["2020JJ5938"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ40945"],"award-info":[{"award-number":["2023JJ40945"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ40872"],"award-info":[{"award-number":["2023JJ40872"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000207"],"award-info":[{"award-number":["82000207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900201"],"award-info":[{"award-number":["81900201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","award":["CXPJJH12000009-123"],"award-info":[{"award-number":["CXPJJH12000009-123"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102748","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T16:38:15Z","timestamp":1760805495000},"page":"102748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Fang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-5820","authenticated-orcid":false,"given":"Shuanghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6956-3226","authenticated-orcid":false,"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102748_bib1","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102748_bib2","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102748_bib3","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102748_bib4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102748_bib5","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30(+) lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.omtn.2025.102748_bib6","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.omtn.2025.102748_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials","volume":"12","author":"Que","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102748_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omtn.2025.102748_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102748_bib11","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtn.2025.102748_bib12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.18335","article-title":"Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis","volume":"198","author":"Shargian","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtn.2025.102748_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","article-title":"Challenges and opportunities of allogeneic donor-derived CAR T cells","volume":"22","author":"Yang","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.omtn.2025.102748_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtn.2025.102748_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.omtn.2025.102748_bib16","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102748_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: Clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2025.102748_bib18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2009.01.019","article-title":"Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses","volume":"15","author":"Gill","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtn.2025.102748_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102748_bib20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ijc.2910160205","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells","volume":"16","author":"Herberman","year":"1975","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102748_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"\u201cNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102748_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.humimm.2004.01.004","article-title":"Regulation of FasL expression in natural killer cells","volume":"65","author":"Chua","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102748_bib31","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102748_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102748_bib33","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","article-title":"Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects","volume":"17","author":"Elahi","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.omtn.2025.102748_bib34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102748_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102619","article-title":"Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors","volume":"24","author":"Portillo","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2025.102748_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115899","article-title":"CAR-NK Cells in the Treatment of Solid Tumors","volume":"22","author":"Wrona","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102748_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102748_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107760","article-title":"Non-viral transfection technologies for next-generation therapeutic T cell engineering","volume":"49","author":"Raes","year":"2021","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.omtn.2025.102748_bib39","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7150\/thno.9246","article-title":"Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes","volume":"4","author":"Zeng","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102748_bib40","doi-asserted-by":"crossref","first-page":"985","DOI":"10.7150\/thno.11938","article-title":"DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition","volume":"5","author":"Wu","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102748_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biomaterials.2015.07.025","article-title":"Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia","volume":"67","author":"Zhao","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102748_bib42","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.7150\/thno.17069","article-title":"Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102748_bib43","doi-asserted-by":"crossref","first-page":"37845","DOI":"10.1021\/acsami.0c07004","article-title":"Aptamer-Directed Protein-Specific Multiple Modifications of Membrane Glycoproteins on Living Cells","volume":"12","author":"Chen","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2025.102748_bib44","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.1021\/jacs.8b04319","article-title":"Engineering a 3D DNA-Logic Gate Nanomachine for Bispecific Recognition and Computing on Target Cell Surfaces","volume":"140","author":"Peng","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102748_bib45","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1002\/anie.202004206","article-title":"In Situ Synthesis of an Aptamer-Based Polyvalent Antibody Mimic on the Cell Surface for Enhanced Interactions between Immune and Cancer Cells","volume":"59","author":"Shi","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102748_bib46","article-title":"Directing Multivalent Aptamer-Receptor Binding on the Cell Surface with Programmable Atom-Like Nanoparticles","volume":"61","author":"Guo","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102748_bib47","doi-asserted-by":"crossref","first-page":"8909","DOI":"10.1016\/j.biomaterials.2013.07.099","article-title":"Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer","volume":"34","author":"Parekh","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102748_bib48","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click Chemistry: Diverse Chemical Function from a Few Good Reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.omtn.2025.102748_bib49","article-title":"Clickable Polysaccharides for Biomedical Applications: A Comprehensive Review","volume":"133","author":"Yazdi","year":"2022","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.omtn.2025.102748_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107192","article-title":"Copper-Free Click Chemistry: Applications in Drug Delivery, Cell Tracking, and Tissue Engineering","volume":"34","author":"Yoon","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2025.102748_bib51","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1021\/acs.bioconjchem.9b00509","article-title":"Novel Liposomal Azido Mannosamine Lipids on Metabolic Cell Labeling and Imaging via Cu-Free Click Chemistry","volume":"30","author":"Shen","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102748_bib52","doi-asserted-by":"crossref","first-page":"15046","DOI":"10.1021\/ja044996f","article-title":"A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems","volume":"126","author":"Agard","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102748_bib53","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/bc100306u","article-title":"Surface functionalization using catalyst-free azide-alkyne cycloaddition","volume":"21","author":"Kuzmin","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102748_bib54","doi-asserted-by":"crossref","first-page":"43359","DOI":"10.1021\/acsami.3c07344","article-title":"Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer","volume":"15","author":"Ma","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2025.102748_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121259","article-title":"Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells","volume":"280","author":"Chen","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102748_bib56","article-title":"Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy","volume":"15","author":"Yang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.omtn.2025.102748_bib57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12672-023-00780-6","article-title":"Natural killer cells modified with a Gpc3 aptamer enhance adoptive immunotherapy for hepatocellular carcinoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.omtn.2025.102748_bib58","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102748_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","article-title":"A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtn.2025.102748_bib60","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The Intersection between Tumor Angiogenesis and Immune Suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2025.102748_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2025.102748_bib62","article-title":"Immunotherapy: Reshape the Tumor Immune Microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102748_bib63","article-title":"Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy","volume":"14","author":"Zhao","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.omtn.2025.102748_bib64","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2144\/000114610","article-title":"Protocol for adhesion and immunostaining of lymphocytes and other non-adherent cells in culture","volume":"63","author":"Tsang","year":"2017","journal-title":"Biotechniques"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:08:56Z","timestamp":1766196536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003026"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102748","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent aptamer engineered and functionalized NK cells for enhanced adoptive immunotherapy in CD30-positive malignant lymphoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102748"}}